Should Immunosuppression After Kidney Transplant Be Adjusted Based on Renal Resistance During Pretransplant Hypothermic Machine Perfusion?


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 12 11 2018
accepted: 04 01 2019
pubmed: 4 9 2019
medline: 21 12 2019
entrez: 4 9 2019
Statut: ppublish

Résumé

The hypothermic machine perfusion reduces delayed graft function after kidney transplant and allows, to some extent, predicting early graft function. However, it is difficult to identify exact perfusion criteria with which to exclude kidneys from transplant or modify post-transplant care. The aim of this study was to analyze whether renal resistance during the fourth hour of hypothermic machine perfusion is useful in the prediction of graft survival and acute rejection. Data on pretransplant hypothermic machine perfusion parameters of 407 transplanted kidneys were available. Receiver operating characteristic curve analysis was performed to find an optimal cutoff value of ratio for predicting a higher risk class of considered group of patients. According to this, patients were divided into 2 groups: those who received kidneys with renal resistance lower than 0.19 mm Hg/mL/min (R1; n = 187) and those who received kidneys with renal resistance equal to or higher than 0.19 mm Hg/mL/min (R2; n = 220). Within R2, we additionally analyzed 2 subgroups: patients who received induction therapy (R2-Ind+; n = 124) and those who did not received induction therapy (R2-Ind-; n = 96). Acute rejection in R1 within 1 month post transplant was 2-fold lower compared with R2 and was 6.4% vs 13.1% (P = .03), respectively. One-year graft survival was higher in R1 compared with R2 and was 94.6% vs 88.5% (P = .03), respectively. Acute rejection in the R2-Ind+ subgroup within 1 month post transplant was 2.46-fold lower compared with the R2-Ind- subgroup and was 8% vs 19.7% (P = .01), respectively. Immunosuppression treatment after transplant should be adjusted to perfusion parameters.

Sections du résumé

BACKGROUND BACKGROUND
The hypothermic machine perfusion reduces delayed graft function after kidney transplant and allows, to some extent, predicting early graft function. However, it is difficult to identify exact perfusion criteria with which to exclude kidneys from transplant or modify post-transplant care. The aim of this study was to analyze whether renal resistance during the fourth hour of hypothermic machine perfusion is useful in the prediction of graft survival and acute rejection.
PATIENTS AND METHODS METHODS
Data on pretransplant hypothermic machine perfusion parameters of 407 transplanted kidneys were available. Receiver operating characteristic curve analysis was performed to find an optimal cutoff value of ratio for predicting a higher risk class of considered group of patients. According to this, patients were divided into 2 groups: those who received kidneys with renal resistance lower than 0.19 mm Hg/mL/min (R1; n = 187) and those who received kidneys with renal resistance equal to or higher than 0.19 mm Hg/mL/min (R2; n = 220). Within R2, we additionally analyzed 2 subgroups: patients who received induction therapy (R2-Ind+; n = 124) and those who did not received induction therapy (R2-Ind-; n = 96).
RESULTS RESULTS
Acute rejection in R1 within 1 month post transplant was 2-fold lower compared with R2 and was 6.4% vs 13.1% (P = .03), respectively. One-year graft survival was higher in R1 compared with R2 and was 94.6% vs 88.5% (P = .03), respectively. Acute rejection in the R2-Ind+ subgroup within 1 month post transplant was 2.46-fold lower compared with the R2-Ind- subgroup and was 8% vs 19.7% (P = .01), respectively.
CONCLUSION CONCLUSIONS
Immunosuppression treatment after transplant should be adjusted to perfusion parameters.

Identifiants

pubmed: 31477422
pii: S0041-1345(18)31454-4
doi: 10.1016/j.transproceed.2019.01.202
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2676-2682

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Michal Wszola (M)

Foundation of Research and Science Development, Otwock, Poland.

Piotr Domagala (P)

Department of General and Transplantation Surgery, Medical University of Warsaw, Poland. Electronic address: piotr.domagal@gmail.com.

Marta Serwanska-Swietek (M)

Foundation of Research and Science Development, Otwock, Poland.

Agata Ostaszewska (A)

Foundation of Research and Science Development, Otwock, Poland; Department of General and Transplantation Surgery, Medical University of Warsaw, Poland.

Agnieszka Perkowska-Ptasinska (A)

Department of Transplant Medicine and Nephrology and Internal Diseases, Medical University of Warsaw, Poland.

Tomasz Piatek (T)

Department of Surgical & Transplant Nursing, Medical University of Warsaw, Poland.

Jolanta Gozdowska (J)

Department of Transplant Medicine and Nephrology and Internal Diseases, Medical University of Warsaw, Poland.

Magdalena Durlik (M)

Department of Transplant Medicine and Nephrology and Internal Diseases, Medical University of Warsaw, Poland.

Andrzej Chmura (A)

Department of General and Transplantation Surgery, Medical University of Warsaw, Poland.

Artur Kwiatkowski (A)

Foundation of Research and Science Development, Otwock, Poland; Department of General and Transplantation Surgery, Medical University of Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH